Dual-Acting Molecules Against Influenza Virus

Dual-Acting Molecules Against Influenza Virus

The one-ligand-one-target-one-disease approach is a tested drug design principle that has been successfully implemented in development of therapeutic agents for human and veterinary diseases. However, the fact is that drugs usually interact with more than one target, so they are pleiotropic. It could be the cause of side effects, however, pleiotropy is a two-edged sword as it may increase the therapeutic effect because many diseases are not caused by a defect in one specific target but based on a plethora of targets.

Our AI-based drug discovery platform allows us to design small molecules able to modulate two different targets thought to be responsible for the certain disease. We currently utilize our platform to develop dual-acting drug candidates against influenza A and B viruses. Our AI-designed molecules are simultaneously acting on two different viral proteins essential for the viral life cycle, thereby increasing the therapeutic effect and resistance barrier for the new class of antivirals.

 

About Influenza Virus
According to the World Health Organization reports, the seasonal influenza virus causes up to 5 mln cases of severe illness and up to 500k deaths per year worldwide. Although seasonal vaccines and antiviral drugs are available, there is a constant need for developing new anti-influenza drugs due to resistance and high genetic variability issues observed among new Influenza virus strains.

Dataset of dual-acting molecules

We have open-sourced our top-performing NCEs for academic use. If you want access to the list of NCEs, please, fill in the form below. A paper describing how we generated and evaluated dual-acting molecules will be published soon.

Request for data